The RI-MUHC researcher will receive the 2024 CIHR-ICRH/CTS Distinguished Lecturer Award in Respiratory Sciences

Jean Bourbeau, MD, has been named the 2024 Distinguished Lecturer in Respiratory Sciences by the Institute of Circulatory and Respiratory Health (ICRH) of the Canadian Institutes of Health Research (CIHR) and by the Canadian Thoracic Society (CTS). This award recognizes individuals who exemplify research excellence, a strong and reputable presence within Canada and on the international scene, and a meaningful impact in mentorship and training. As the recipient, Dr. Bourbeau will deliver the keynote lecture at the Canadian Respiratory Conference in April 2024.

Dr. Bourbeau is a clinician scientist, professor, and researcher at McGill University, and a senior scientist at the Research Institute of the McGill University Health Centre (RI-MUHC). At the RI-MUHC he conducts research in the Translational Research in Respiratory Diseases Program and at the Centre for Outcomes Research and Evaluation, and he is former director of the Centre for Innovative Medicine. He is a Fellow of the Canadian Academy of Health Sciences (FCAHS) and has received numerous prestigious awards, including the Distinguished Scientist Award from McGill University (2020-2025) and the Distinguished CHEST Educator from the American College of Chest Physicians (2017-2022).

Internationally recognized for his expertise in chronic obstructive pulmonary disease (COPD), Dr. Bourbeau actively participates in various scientific committees and has served as the president and remains on the board of the Canadian Thoracic Society (CTS). His research includes notable contributions like the “Living Well with COPD” self-management program and the Canadian Cohort Obstructive Lung Disease (CanCOLD) prospective study, over 15M$ in grant support since 2009, CIHR grants, over 100 sub-studies and over 80 publications. In the last decades he has secured substantial research funding, published over 400 papers, reviews, and chapters, and his work has significantly influenced clinical practice worldwide.

He is the principal investigator for various investigator-initiated clinical trials, addressing both non-pharmacological interventions and drug or device interventions for COPD patients. His dedication extends to advancing clinical trial training platforms as he leads the CIHR Clinical Training Trial Platform, CANTRAIN, with 11.3 million dollars in funding (2022-2025).

Dr. Bourbeau has made significant contributions to national and international guidelines, including the GOLD Reports, CTS COPD pharmacotherapy Guidelines, American College of Chest Physicians/CTS Guidelines on prevention of COPD exacerbations, and American Thoracic/European Respiratory Society Guidelines on Pulmonary Rehabilitation.

Congratulations, Dr. Bourbeau!

Related news

Leaders in COPD care and research